Logo

Life Technologies Plans Share Repurchase

Jan 11, 2011

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) - Life Technologies said today that its board has authorized the repurchase of up to $500 million in shares.

The program authorizes the company's management to repurchase shares on the open market or in privately negotiated transactions.

"Given our continued outlook for significant free cash flow generation, we believe the company is in strong financial position to meet both our capital requirements to invest for future growth, while also returning excess cash to shareholders," Gregory Lucier, CEO and chairman of Life Tech, said in a statement.

Filed under

stock repurchase
Thermo Fisher Scientific
Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.